PD-1 inhibitor induced alopecia areata

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Immune checkpoint modulators, particularly programmed death 1 (PD-1) inhibitors, are increasingly used for metastatic melanoma and other cancers.
• These therapies can lead to immune-related adverse events, including various skin conditions.

Observation:

• Alopecia is a recognized side effect associated with these immunotherapies.
• Previous reports have primarily focused on chemotherapy-induced alopecia.

Findings:

• This report details a rare case of alopecia areata in a patient receiving monotherapy with pembrolizumab, a PD-1 inhibitor.
• The patient developed alopecia areata while on treatment for metastatic melanoma.

Implications:

• Dermatologists must be aware of alopecia areata as a potential adverse event of PD-1 inhibitors.
• Early recognition and appropriate management are crucial to reduce patient morbidity and improve treatment outcomes.